Hera Biotech is developing a new diagnostic test for endometriosis that is more accurate and less invasive than current methods. The company was founded by Somer Baburek, a former venture capitalist, who saw a need for better diagnostic tools for this condition. Hera Biotech is currently seeking funding to finalize product development and launch its first diagnostic product to market. Baburek, the visionary behind San Antonio, Texas-based Hera Biotech, has embarked on a mission to reshape the landscape of women’s health, particularly in endometriosis diagnosis and treatment. Her journey began in February 2020, fueled by a deep passion for women’s health, a personal connection to the challenges of endometriosis, and her career working in venture capital. The company’s name, Hera, is a nod to the Greek goddess of women, marriage, and childbirth, symbolizing the company’s dedication to improving women’s lives. Hera Biotech’s primary focus is on the diagnosis and progression tracking of endometriosis, a debilitating condition that affects millions of women worldwide. Baburek’s personal experiences with the struggles her sister and niece had with endometriosis further ignited her determination to find better solutions for this often misunderstood condition. She recognized the limitations of current diagnostic methods—which frequently involve invasive procedures—and sought to develop a more accurate and patient-friendly approach.

Full report : Hera Biotech is developing an non-invasive Endometriosis solution.